The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
The investment bank said that Danaher, Illumina, Qiagen, and Thermo Fisher Scientific were its top picks.
The investment bank noted that Hologic could be the "biggest beneficiary from tax reform" in its coverage with a potential 8 percent benefit to earnings per share.
Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.
The investment firm noted that Myriad is still trying to stabilize its hereditary cancer testing business while diversifying its portfolio to drive future growth.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
The investment bank also assigned a price target of $194 per share to the life science tools and diagnostics firm's stock.
Analysts have released notes to investors refuting the report's claims, calling the short thesis "flawed," and reiterating their ratings for Exact's stock.
The investment bank gave Exact Sciences' shares a price target of $30, and said it expects higher uptake of the Cologuard test and an increase in payor contracts.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.